Clinical Trial Search

Primary: Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) — 0; 0; 0; 0 Participants

Primary: Time to Composite of All-Cause Mortality and Non-Fatal Cardiovascular Events (Myocardial Infarction, Stroke) Defined as Time Between First Dose of Study Medication and…

Primary: Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) — 0 Participants

Primary: Proportion of Subjects With Average Serum Potassium Values ≤ 5.1 mmol/L — 0.875; 0.822; 0.797; 0.862 Proportion of Participants

Primary: Proportion of Participants Who Are Able to Pair & Apply a Patch Independently & Successfully by the End of the Week 8 Study Visit as Defined by a Score of 91 to 100 on…

Primary: Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) — 2; 0 Participants

Primary: Number of Participants With Paroxymal Atrial Fibrillation (PAF) — 150; 0 Participants — p=0.054

Primary: Percentage of Participants With SLE Responder Index (SRI) Response at Week 52 — 43.6; 52.8 Percentage of participants

Primary: Reponse Rate of the Combination Sorafenib and Temsirolimus in I-131 Refractory Thyroid Cancer. — 8; 21; 1 Participants

Primary: Change in ON Time as Measured by Parkinson's Disease Diary — 3.74; 0.72 hours

Primary: Overall Mean Change in A1C — 0.26 percentage

Primary: Change in Mean Number of Nocturnal Voids From Baseline — -1.63; -1.29 Voids — p=0.112

Primary: Percentage of Subjects Who Have a ≥4-point Improvement in the Weekly Mean Score of Axillary Sweating Daily Diary (ASDD) Item #2 From Baseline at Week 4 — 66.1; 26.9…

Primary: Percentage of Subjects Who Have a ≥4-point Improvement in the Weekly Mean Score of ASDD Item #2 From Baseline at Week 4 — 52.8; 28.3 percent of subjects — p=<0.001

Primary: Average Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of the Principal Muscle Group at Weeks 4 and 6 — -1.87; -1.92; -1.21 score on a scale…